Compare Citius Pharmaceuticals Inc (CTXR) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street PDR S&P Retail ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while State Street PDR S&P Retail ETF trades at $83.76 (market cap $389.66M). The key difference: State Street PDR S&P Retail ETF is far larger — about 28.6× Citius Pharmaceuticals Inc's market cap, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and State Street PDR S&P Retail ETF for 44 Days on average.
| CTXR | XRT | |
|---|---|---|
Market Cap | $13.62M | $389.66M |
Volume | 132,438 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.82 | $92.35 |
52-Week Low | $0.48 | $77.28 |
Typical Hold Time | 16 Days | 44 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
XRT (SPDR S&P Retail ETF) trades at $82.91, showing minimal daily movement with a slight decline of 0.05%. Technical indicators signal a bearish trend overall, with moving averages particularly negative. The ETF faces headwinds from higher interest rates and inflation impacting consumer spending, though recent retail sales data showed a strong August rebound. Analyst sentiment remains cautious with expectations of continued underperformance against broader market indices.
The retail sector faces macroeconomic pressures including inflation and rising rates that weigh on consumer discretionary spending. While holiday sales projections exceed $1 trillion, selective consumer behavior favors value-oriented retailers. Near-term performance depends on Fed policy direction and consumer resilience during the critical holiday season, with technical resistance at $83-$84 levels limiting upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
